Callan Family Office LLC Has $1.03 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Callan Family Office LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 30.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,072 shares of the company’s stock after purchasing an additional 1,640 shares during the quarter. Callan Family Office LLC’s holdings in Johnson & Johnson were worth $1,034,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Alliance Wealth Advisors LLC UT raised its position in Johnson & Johnson by 1.4% in the 4th quarter. Alliance Wealth Advisors LLC UT now owns 4,714 shares of the company’s stock worth $739,000 after purchasing an additional 64 shares during the period. Carolinas Wealth Consulting LLC lifted its stake in shares of Johnson & Johnson by 0.4% in the 4th quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock valued at $2,643,000 after acquiring an additional 64 shares during the last quarter. Epic Trust Investment Advisors LLC boosted its holdings in Johnson & Johnson by 3.6% during the 2nd quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock valued at $268,000 after acquiring an additional 64 shares during the period. Verity Asset Management Inc. grew its position in Johnson & Johnson by 2.0% during the 4th quarter. Verity Asset Management Inc. now owns 3,268 shares of the company’s stock worth $512,000 after acquiring an additional 65 shares during the last quarter. Finally, Forza Wealth Management LLC increased its stake in Johnson & Johnson by 0.8% in the 2nd quarter. Forza Wealth Management LLC now owns 8,742 shares of the company’s stock worth $1,278,000 after purchasing an additional 66 shares during the period. 69.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on JNJ. Morgan Stanley increased their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Sanford C. Bernstein boosted their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Friday, August 16th. Finally, TD Cowen reduced their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Stock Up 0.3 %

NYSE:JNJ traded up $0.52 during trading hours on Monday, reaching $164.65. 6,869,212 shares of the company traded hands, compared to its average volume of 7,299,698. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $166.21. The stock has a market capitalization of $396.26 billion, a P/E ratio of 10.26, a P/E/G ratio of 2.63 and a beta of 0.52. The business’s 50-day moving average price is $154.30 and its two-hundred day moving average price is $153.26. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.80 EPS. Analysts predict that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.01%. Johnson & Johnson’s payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.